GLOMERULONEPHRITIS, IGA
Clinical trials for GLOMERULONEPHRITIS, IGA explained in plain language.
Never miss a new study
Get alerted when new GLOMERULONEPHRITIS, IGA trials appear
Sign up with your email to follow new studies for GLOMERULONEPHRITIS, IGA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to halt silent kidney damage
Disease control Recruiting nowThis study is testing whether adding an investigational oral drug called iptacopan to standard supportive care can reduce harmful immune activity and slow kidney damage in adults with IgA nephropathy. Researchers will compare kidney biopsies from 20 participants before and after …
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Kidney disease drug faces Long-Term safety test
Disease control Recruiting nowThis study follows patients who previously participated in zigakibart trials to monitor long-term safety and effectiveness for IgA nephropathy, a chronic kidney disease. About 220 adults will receive the drug every two weeks for up to two years while researchers track side effect…
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC